Brief: Lisata Therapeutics Announces Outcome Of Interim Futility Analysis For Its Phase 2B Trial Of LSTA1 In Metastatic Pancreatic Ductal Adenocarcinoma
06/09/2023 16:19
Sept 6 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES OUTCOME OF INTERIM FUTILITY
ANALYSIS FOR ITS PHASE 2B ASCEND TRIAL OF LSTA1 IN METASTATIC
PANCREATIC DUCTAL ADENOCARCINOMA
* LISATA THERAPEUTICS INC - ASCEND TRIAL WILL CONTINUE AS
PLANNED
WITHOUT MODIFICATION
* LISATA THERAPEUTICS INC - ASCEND CONTINUES TO ENROLL AT A
RAPID
PACE AND WE AFFIRM OUR PROJECTION OF LAST PATIENT IN DURING
FIRST HALF OF 2024
Source text for Eikon: ID:nGNX9qtJN7
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco